CN1856473A - 异喹啉酮钾通道抑制剂 - Google Patents

异喹啉酮钾通道抑制剂 Download PDF

Info

Publication number
CN1856473A
CN1856473A CNA2004800273785A CN200480027378A CN1856473A CN 1856473 A CN1856473 A CN 1856473A CN A2004800273785 A CNA2004800273785 A CN A2004800273785A CN 200480027378 A CN200480027378 A CN 200480027378A CN 1856473 A CN1856473 A CN 1856473A
Authority
CN
China
Prior art keywords
group
compound
ring
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800273785A
Other languages
English (en)
Chinese (zh)
Inventor
R·伊萨克斯
C·J·丁斯莫尔
C·J·麦金太尔
L·S·佩尼
D·A·克莱尔蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1856473A publication Critical patent/CN1856473A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CNA2004800273785A 2003-09-23 2004-09-22 异喹啉酮钾通道抑制剂 Pending CN1856473A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50513803P 2003-09-23 2003-09-23
US60/505,138 2003-09-23

Publications (1)

Publication Number Publication Date
CN1856473A true CN1856473A (zh) 2006-11-01

Family

ID=34392983

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800273785A Pending CN1856473A (zh) 2003-09-23 2004-09-22 异喹啉酮钾通道抑制剂

Country Status (7)

Country Link
US (1) US7781457B2 (enExample)
EP (1) EP1667977A4 (enExample)
JP (1) JP4719152B2 (enExample)
CN (1) CN1856473A (enExample)
AU (1) AU2004276267B2 (enExample)
CA (1) CA2539541C (enExample)
WO (1) WO2005030727A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103864684A (zh) * 2012-12-07 2014-06-18 天津科技大学 一种新颖的3,4-二氢-1(2h)异喹啉类衍生物的合成与抗肿瘤药物的应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004276236B2 (en) * 2003-09-23 2008-01-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
WO2005030726A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
EP1667978B1 (en) * 2003-09-23 2013-09-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
US7763614B2 (en) * 2003-09-23 2010-07-27 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
AU2005267884B2 (en) 2004-07-29 2011-04-21 Merck Sharp & Dohme Corp. Potassium channel inhibitors
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
EP1922311A2 (en) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Acyclic ikur inhibitors
WO2007121453A2 (en) * 2006-04-17 2007-10-25 The Regents Of The University Of California 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
NZ572231A (en) * 2006-04-27 2010-12-24 Sanofi Aventis Deutschland Inhibitors of the task-1 and task-3 ion channel
DE102006019589A1 (de) * 2006-04-27 2007-10-31 Sanofi-Aventis Deutschland Gmbh Inhibitoren des TASK-1 und Task-3 Ionenkanals
CA2659251C (en) 2006-07-10 2016-06-14 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
BRPI0806371A2 (pt) 2007-01-22 2011-09-13 Gtx Inc agentes ligação de receptor nuclear
WO2010039538A2 (en) 2008-09-23 2010-04-08 Georgetown University Flavivirus inhibitors and methods for their use
AU2009298877A1 (en) 2008-09-23 2010-04-08 Georgetown University Viral and fungal inhibitors
US9273059B2 (en) 2009-08-24 2016-03-01 Lumiphore, Inc. Macrocyclic HOPO chelators
MX2013002295A (es) * 2010-09-01 2013-05-09 Gruenenthal Gmbh 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69110828T2 (de) * 1990-10-16 1995-11-30 Takeda Chemical Industries Ltd Heterozyklische Aminderivate, deren Herstellung und deren Verwendung.
TW241258B (enExample) 1992-04-15 1995-02-21 Takeda Pharm Industry Co Ltd
NO179904C (no) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
TW263498B (enExample) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
JPH10298164A (ja) * 1997-02-27 1998-11-10 Tanabe Seiyaku Co Ltd イソキノリノン誘導体、その製法及びその合成中間体
WO1998038168A1 (en) * 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
JP2000072751A (ja) * 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
US6444685B1 (en) * 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
AU2002212969B2 (en) * 2000-09-20 2006-07-06 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
BR0206831A (pt) * 2001-02-02 2004-07-06 Takeda Chemical Industries Ltd Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
US7402595B2 (en) * 2002-02-13 2008-07-22 Takeda Pharmaceutical Company Limited JNK inhibitor
AU2004276236B2 (en) * 2003-09-23 2008-01-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
US7763614B2 (en) * 2003-09-23 2010-07-27 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
EP1667978B1 (en) * 2003-09-23 2013-09-04 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
WO2005030726A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103864684A (zh) * 2012-12-07 2014-06-18 天津科技大学 一种新颖的3,4-二氢-1(2h)异喹啉类衍生物的合成与抗肿瘤药物的应用

Also Published As

Publication number Publication date
EP1667977A4 (en) 2009-09-09
US7781457B2 (en) 2010-08-24
CA2539541C (en) 2010-06-29
CA2539541A1 (en) 2005-04-07
JP2007506748A (ja) 2007-03-22
WO2005030727A1 (en) 2005-04-07
US20060270704A1 (en) 2006-11-30
EP1667977A1 (en) 2006-06-14
JP4719152B2 (ja) 2011-07-06
AU2004276267A1 (en) 2005-04-07
AU2004276267B2 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
CN1856307A (zh) 喹啉钾通道抑制剂
CN1856474A (zh) 异喹啉钾通道抑制剂
CN1856473A (zh) 异喹啉酮钾通道抑制剂
CN1856476A (zh) 异喹啉酮钾通道抑制剂
CN1856475A (zh) 异喹啉钾通道抑制剂
CN1025999C (zh) 咪唑并[4，5-b]喹啉氧烷酰胺的制备方法
CN1189166C (zh) Fc受体调节剂及其应用
CN1856477A (zh) 异喹啉钾通道抑制剂
CN1125064C (zh) 3－吡啶基对映体及其作为镇痛剂的用途
CN1327444A (zh) 肾上腺素能α1β受体拮抗药
CN1993347A (zh) 钾通道抑制剂
CN1249033C (zh) 环腺苷酸－特异性磷酸二酯酶抑制剂
CN1221544C (zh) 吡唑环腺苷酸－特异性磷酸二酯酶抑制剂
CN1246311C (zh) 抑制环腺苷酸特异性磷酸二酯酶的吡咯烷
CN1351497A (zh) 用作山梨醇脱氢酶抑制剂的氨基嘧啶类化合物
CN1933834A (zh) 吲唑甲酰胺衍生物在制备用于治疗和预防疟疾的药物中的用途
CN1543346A (zh) 新化合物
CN1454211A (zh) 作为Xa因子抑制剂的含氮杂双环化合物
CN1674899A (zh) IkB激酶抑制剂用于治疗疼痛的用途
CN1585751A (zh) 喹啉化合物
CN1441783A (zh) 含二氰基吡啶衍生物的药物
CN1416420A (zh) 1,2,3,4－四氢异喹啉的衍生物
HK1045519A1 (en) 1-(p-thienylbenzyl)-imidazoles as angiotensin-(1-7)receptor agonists, method for the production and the utilization thereof and pharmaceutical preparations containing said compounds
CN1713910A (zh) 作为p38激酶抑制剂的氮杂吲哚衍生物
CN1856310A (zh) 喹唑啉钾通道抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication